Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T16:04:02.281Z Has data issue: false hasContentIssue false

31 - Clozapine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Clozaril, Clopine, Fazaclo ODT, Versacloz, Denzapine, Zaponex, Leponex Generic?

• Yes

Class

• Antipsychotic

Commonly Prescribed for

(FDA approved in bold)

Treatment-resistant schizophrenia

Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder

• Dyskinesia

• Psychosis in patients with Parkinson’s disease (PD) or dementia with Lewy bodies (DLB)

• Bipolar disorder (treatment resistant)

• Severe psychosis

• Post-traumatic stress disorder

How the Drug Works

• It is a dibenzodiazepine derivative of high affinity for 5-HT2, α1/2, M1–5, and H1 receptors and moderate affinity for D2/4 receptors. The effect is likely from antagonizing D2 receptors (for positive symptoms) and 5-HT2A receptors (for negative symptoms)

How Long Until It Works

• Psychosis: may be effective in days, more commonly takes weeks or months to determine best dose and achieve best clinical effect

If It Works

• Continue to use at lowest required dose with appropriate monitoring. Patients with PD and DLB may improve more than patients with schizophrenia

If It Doesn't Work

• Increase dose

• In psychosis related to PD or DLB, eliminate or reduce dose of offending medications, such as dopamine agonists or amantadine

Best Augmenting Combos for Partial Response or Treatment-Resistance

• PD and DLB: cholinesterase inhibitors may reduce psychotic symptoms

• In dementia, SSRIs may improve behavioral symptoms

Tests

• Obligatory. Prior to starting treatment, obtain CBC, including white count and absolute neutrophil count. Repeat weekly for 6 weeks, then every other week as long as patient is on medication and for 4 weeks after stopping. Also monitor blood sugar periodically

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Motor AEs: blocking of D2 receptors

• Sedation, weight gain: blocking of H1 receptors

• Hypotension: blocking of α1/2-adrenergic receptors

• Dry mouth, constipation: blocking of muscarinic receptors (anticholinergic)

Notable AEs

• Most common: CNS (sedation, dizziness/vertigo, headache, tremor); cardiovascular (tachycardia, orthostatic hypotension, syncope); autonomic (hypersalivation, sweating, dry mouth, visual disturbance, urinary retention); GI reaction (GI hypomotility, constipation, nausea); and fever

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 114 - 117
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Clozapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.032
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Clozapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.032
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Clozapine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.032
Available formats
×